- Home
- TRNS vs AVTX Comparison
TRNS vs AVTX Comparison
Compare TRNS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNS | AVTX |
|---|---|---|
| Founded | 1964 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.5M | 956.7M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TRNS | AVTX |
|---|---|---|
| Price | $85.20 | $18.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $116.00 | $40.57 |
| AVG Volume (30 Days) | 123.8K | ★ 1.5M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $331,877,000.00 | $27,813,137.00 |
| Revenue This Year | $21.75 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | $153.18 | ★ N/A |
| Revenue Growth | 19.20 | ★ 2312.27 |
| 52 Week Low | $50.23 | $6.21 |
| 52 Week High | $95.22 | $24.27 |
Technical Indicators
Market Signals| Indicator | TRNS | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 51.08 |
| Support Level | $67.74 | $17.32 |
| Resistance Level | $85.20 | $19.06 |
| Average True Range (ATR) | 3.61 | 1.17 |
| MACD | -0.67 | -0.22 |
| Stochastic Oscillator | 3.03 | 18.81 |
Price Performance
Historical ComparisonAbout TRNS Transcat Inc.
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.